Healthcare ❯ Pharmaceuticals

Gene Therapy

Clinical Trials Patient Safety Adverse Events ZEVASKYN Hemophilia Treatment Regulatory Approval Cost of Treatment Rare Diseases FDA Regulation Duchenne Muscular Dystrophy

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

Early sales suggest the launch can grow without stretching the balance sheet.

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death